Role of an isomorphic desolvate in dissolution failures of an erythromycin tablet formulation

The investigation of dissolution failures for erythromycin dihydrate tablet formulation over a 12‐month period using a near‐infrared spectroscopy technique revealed the role of a desolvated dihydrate in the retardation of dissolution. Near infrared spectroscopy (NIR) indicated a dehydrated dihydrate...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical sciences 1999-11, Vol.88 (11), p.1222-1227
Main Authors: Bauer, John F., Dziki, Walter, Quick, John E.
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - chemistry
Biological and medical sciences
Desiccation
Drug Stability
Erythromycin - administration & dosage
Erythromycin - chemistry
Excipients - chemistry
General pharmacology
Magnesium Hydroxide - chemistry
Medical sciences
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Solubility
Spectroscopy, Near-Infrared
Tablets
Water - chemistry
X-Ray Diffraction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4299-85daac19fdc5afba9e6e3bf04b305b30c1471db1d82d5136146bd5459c875e1c3
cites cdi_FETCH-LOGICAL-c4299-85daac19fdc5afba9e6e3bf04b305b30c1471db1d82d5136146bd5459c875e1c3
container_end_page 1227
container_issue 11
container_start_page 1222
container_title Journal of pharmaceutical sciences
container_volume 88
creator Bauer, John F.
Dziki, Walter
Quick, John E.
description The investigation of dissolution failures for erythromycin dihydrate tablet formulation over a 12‐month period using a near‐infrared spectroscopy technique revealed the role of a desolvated dihydrate in the retardation of dissolution. Near infrared spectroscopy (NIR) indicated a dehydrated dihydrate of erythromycin is produced during formulation and gradually binds with Mg(OH)2. The binding delays the process of dissolution. NIR was used to successfully predict that humidifying the tablets would reverse the binding and increase the dissolution rate.
doi_str_mv 10.1021/js9900102
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69285778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354915509052</els_id><sourcerecordid>69285778</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4299-85daac19fdc5afba9e6e3bf04b305b30c1471db1d82d5136146bd5459c875e1c3</originalsourceid><addsrcrecordid>eNp10U1rFTEUBuBQLO1t7cI_ILMQodDRfExmJku59tNSRSuuJGSSE5qamVyTmbb33zdlLtWFLkJy4MkJeQ9Crwh-RzAl72-TEBjn4xZaEE5xWWPSvEALjCktGa_ELtpL6RZjXGPOd9AuwbyucMMW6OfX4KEItlBD4VLoQ1zdOF0YSMHfqREKNxTGpVxNowtDYZXzU4S0uQJxPd7E0K91dqPqPIyFDbGfvHriL9G2VT7BwWbfR99Pjq-XZ-Xl59Pz5YfLUldUiLLlRilNhDWaK9spATWwzuKqY5jnpUnVENMR01LDCatJVXeGV1zotuFANNtHb-e-qxh-T5BG2bukwXs1QJiSrAVtedO0GR7OUMeQUgQrV9H1Kq4lwfIpS_mcZbavN02nrgfzl5zDy-DNBqiklbdRDdqlP47mKVCS2dHM7p2H9f8flBdfvhGReTlzl0Z4eOYq_pJ1wxouf1ydyrOTj9WnKybkMns2e8gB3zmIMmkHgwbjIuhRmuD-8blHfiqqxg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69285778</pqid></control><display><type>article</type><title>Role of an isomorphic desolvate in dissolution failures of an erythromycin tablet formulation</title><source>Wiley Online Library - AutoHoldings Journals</source><source>ScienceDirect (Online service)</source><creator>Bauer, John F. ; Dziki, Walter ; Quick, John E.</creator><creatorcontrib>Bauer, John F. ; Dziki, Walter ; Quick, John E.</creatorcontrib><description>The investigation of dissolution failures for erythromycin dihydrate tablet formulation over a 12‐month period using a near‐infrared spectroscopy technique revealed the role of a desolvated dihydrate in the retardation of dissolution. Near infrared spectroscopy (NIR) indicated a dehydrated dihydrate of erythromycin is produced during formulation and gradually binds with Mg(OH)2. The binding delays the process of dissolution. NIR was used to successfully predict that humidifying the tablets would reverse the binding and increase the dissolution rate.</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1021/js9900102</identifier><identifier>PMID: 10564073</identifier><identifier>CODEN: JPMSAE</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>Anti-Bacterial Agents - administration &amp; dosage ; Anti-Bacterial Agents - chemistry ; Biological and medical sciences ; Desiccation ; Drug Stability ; Erythromycin - administration &amp; dosage ; Erythromycin - chemistry ; Excipients - chemistry ; General pharmacology ; Magnesium Hydroxide - chemistry ; Medical sciences ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Solubility ; Spectroscopy, Near-Infrared ; Tablets ; Water - chemistry ; X-Ray Diffraction</subject><ispartof>Journal of pharmaceutical sciences, 1999-11, Vol.88 (11), p.1222-1227</ispartof><rights>1999 Wiley‐Liss, Inc. and the American Pharmaceutical Association</rights><rights>Copyright © 1999 Wiley‐Liss, Inc. and the American Pharmaceutical Association</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4299-85daac19fdc5afba9e6e3bf04b305b30c1471db1d82d5136146bd5459c875e1c3</citedby><cites>FETCH-LOGICAL-c4299-85daac19fdc5afba9e6e3bf04b305b30c1471db1d82d5136146bd5459c875e1c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1021%2Fjs9900102$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0022354915509052$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,1414,3538,27907,27908,45557,45558,45763</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1201721$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10564073$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bauer, John F.</creatorcontrib><creatorcontrib>Dziki, Walter</creatorcontrib><creatorcontrib>Quick, John E.</creatorcontrib><title>Role of an isomorphic desolvate in dissolution failures of an erythromycin tablet formulation</title><title>Journal of pharmaceutical sciences</title><addtitle>J. Pharm. Sci</addtitle><description>The investigation of dissolution failures for erythromycin dihydrate tablet formulation over a 12‐month period using a near‐infrared spectroscopy technique revealed the role of a desolvated dihydrate in the retardation of dissolution. Near infrared spectroscopy (NIR) indicated a dehydrated dihydrate of erythromycin is produced during formulation and gradually binds with Mg(OH)2. The binding delays the process of dissolution. NIR was used to successfully predict that humidifying the tablets would reverse the binding and increase the dissolution rate.</description><subject>Anti-Bacterial Agents - administration &amp; dosage</subject><subject>Anti-Bacterial Agents - chemistry</subject><subject>Biological and medical sciences</subject><subject>Desiccation</subject><subject>Drug Stability</subject><subject>Erythromycin - administration &amp; dosage</subject><subject>Erythromycin - chemistry</subject><subject>Excipients - chemistry</subject><subject>General pharmacology</subject><subject>Magnesium Hydroxide - chemistry</subject><subject>Medical sciences</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Solubility</subject><subject>Spectroscopy, Near-Infrared</subject><subject>Tablets</subject><subject>Water - chemistry</subject><subject>X-Ray Diffraction</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNp10U1rFTEUBuBQLO1t7cI_ILMQodDRfExmJku59tNSRSuuJGSSE5qamVyTmbb33zdlLtWFLkJy4MkJeQ9Crwh-RzAl72-TEBjn4xZaEE5xWWPSvEALjCktGa_ELtpL6RZjXGPOd9AuwbyucMMW6OfX4KEItlBD4VLoQ1zdOF0YSMHfqREKNxTGpVxNowtDYZXzU4S0uQJxPd7E0K91dqPqPIyFDbGfvHriL9G2VT7BwWbfR99Pjq-XZ-Xl59Pz5YfLUldUiLLlRilNhDWaK9spATWwzuKqY5jnpUnVENMR01LDCatJVXeGV1zotuFANNtHb-e-qxh-T5BG2bukwXs1QJiSrAVtedO0GR7OUMeQUgQrV9H1Kq4lwfIpS_mcZbavN02nrgfzl5zDy-DNBqiklbdRDdqlP47mKVCS2dHM7p2H9f8flBdfvhGReTlzl0Z4eOYq_pJ1wxouf1ydyrOTj9WnKybkMns2e8gB3zmIMmkHgwbjIuhRmuD-8blHfiqqxg</recordid><startdate>199911</startdate><enddate>199911</enddate><creator>Bauer, John F.</creator><creator>Dziki, Walter</creator><creator>Quick, John E.</creator><general>Elsevier Inc</general><general>John Wiley &amp; Sons, Inc</general><general>Wiley</general><general>American Pharmaceutical Association</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199911</creationdate><title>Role of an isomorphic desolvate in dissolution failures of an erythromycin tablet formulation</title><author>Bauer, John F. ; Dziki, Walter ; Quick, John E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4299-85daac19fdc5afba9e6e3bf04b305b30c1471db1d82d5136146bd5459c875e1c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Anti-Bacterial Agents - administration &amp; dosage</topic><topic>Anti-Bacterial Agents - chemistry</topic><topic>Biological and medical sciences</topic><topic>Desiccation</topic><topic>Drug Stability</topic><topic>Erythromycin - administration &amp; dosage</topic><topic>Erythromycin - chemistry</topic><topic>Excipients - chemistry</topic><topic>General pharmacology</topic><topic>Magnesium Hydroxide - chemistry</topic><topic>Medical sciences</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Solubility</topic><topic>Spectroscopy, Near-Infrared</topic><topic>Tablets</topic><topic>Water - chemistry</topic><topic>X-Ray Diffraction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bauer, John F.</creatorcontrib><creatorcontrib>Dziki, Walter</creatorcontrib><creatorcontrib>Quick, John E.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bauer, John F.</au><au>Dziki, Walter</au><au>Quick, John E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of an isomorphic desolvate in dissolution failures of an erythromycin tablet formulation</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J. Pharm. Sci</addtitle><date>1999-11</date><risdate>1999</risdate><volume>88</volume><issue>11</issue><spage>1222</spage><epage>1227</epage><pages>1222-1227</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><coden>JPMSAE</coden><abstract>The investigation of dissolution failures for erythromycin dihydrate tablet formulation over a 12‐month period using a near‐infrared spectroscopy technique revealed the role of a desolvated dihydrate in the retardation of dissolution. Near infrared spectroscopy (NIR) indicated a dehydrated dihydrate of erythromycin is produced during formulation and gradually binds with Mg(OH)2. The binding delays the process of dissolution. NIR was used to successfully predict that humidifying the tablets would reverse the binding and increase the dissolution rate.</abstract><cop>New York</cop><pub>Elsevier Inc</pub><pmid>10564073</pmid><doi>10.1021/js9900102</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3549
ispartof Journal of pharmaceutical sciences, 1999-11, Vol.88 (11), p.1222-1227
issn 0022-3549
1520-6017
language eng
recordid cdi_proquest_miscellaneous_69285778
source Wiley Online Library - AutoHoldings Journals; ScienceDirect (Online service)
subjects Anti-Bacterial Agents - administration & dosage
Anti-Bacterial Agents - chemistry
Biological and medical sciences
Desiccation
Drug Stability
Erythromycin - administration & dosage
Erythromycin - chemistry
Excipients - chemistry
General pharmacology
Magnesium Hydroxide - chemistry
Medical sciences
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Solubility
Spectroscopy, Near-Infrared
Tablets
Water - chemistry
X-Ray Diffraction
title Role of an isomorphic desolvate in dissolution failures of an erythromycin tablet formulation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T21%3A18%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20an%20isomorphic%20desolvate%20in%20dissolution%20failures%20of%20an%20erythromycin%20tablet%20formulation&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Bauer,%20John%20F.&rft.date=1999-11&rft.volume=88&rft.issue=11&rft.spage=1222&rft.epage=1227&rft.pages=1222-1227&rft.issn=0022-3549&rft.eissn=1520-6017&rft.coden=JPMSAE&rft_id=info:doi/10.1021/js9900102&rft_dat=%3Cproquest_cross%3E69285778%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4299-85daac19fdc5afba9e6e3bf04b305b30c1471db1d82d5136146bd5459c875e1c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=69285778&rft_id=info:pmid/10564073&rfr_iscdi=true